Document is current
Any future updates will be listed below
-
Authors
Herzog, Chiara M. S. https://orcid.org/0000-0002-1572-498X
Theeuwes, Bente
Jones, Allison
Evans, Iona https://orcid.org/0000-0002-0225-3154
Bjørge, Line https://orcid.org/0000-0002-0240-2770
Zikan, Michal
Cibula, David https://orcid.org/0000-0001-6387-9356
Harbeck, Nadia https://orcid.org/0000-0002-9744-7372
Colombo, Nicoletta
Pashayan, Nora
Widschwendter, Martin https://orcid.org/0000-0002-7778-8380
- License Information
-
More Information
Article History
Received: 12 February 2024
Accepted: 15 October 2024
First Online: 2 April 2025
Competing interests
: C.M.S.H. and M.W. are shareholders of Sola Diagnostics GmbH, which holds an exclusive license to the intellectual property that protects the commercialization of cervical sample DNA methylation-based tests (WID-qtBC, WID-BC). At the time of the publication of this manuscript, a UK patent application is pending for work described in this manuscript. A.J. and I.E. are named inventors on a patent of the WID-BC test. N.C. has reported fees for advisory board membership for AstraZeneca, Clovis Oncology, Eisai, GSK, Immunogen, Mersana, MSD/Merck, Nuvation Bio, Oncxerna, Pieris, Roche, Novocure; fees as an invited speaker for AstraZeneca, Clovis Oncology, GSK, MSD/Merck, Eisai, and institutional research grants from AstraZeneca, Roche, GSK. She has also reported non-remunerated activities as a member of the ESMO Guidelines Steering Committee and chair of the Scientific Committee of ACTO (Alleanza contro il tumore ovarico). The remaining authors declare no competing interests.
